Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats

Abstract. Rationale: Human positron emission tomography (PET) shows that striatal dopamine D2 receptor occupancy predicts extrapyramidal side effects (EPS). Patients showed a clinical response with ≥65% D2 occupancy, but EPS only when D2 occupancy >78%. Catalepsy and the selective suppression of conditioned avoidance response (CAR) are often used as animal models to predict EPS and antipsychotic effect, respectively. However, the quantitative relationship between striatal D2 occupancy and effects in these models is not known. Objectives: The present study intended to investigate the relationship between animal catalepsy, suppression of CAR, and D2 receptor blockade using a method of evaluating D2 receptor occupancy similar in principle to that used in patients. Methods: In vivo binding of [11C]-raclopride and [3H]-raclopride was compared. Doses of cold raclopride were chosen to provide a D2 occupancy from 0 to 95%. The relationship between dose/time course of catalepsy and D2 occupancy was assessed. Effects of raclopride on conditioned avoidance response (CAR) behavior were tested. Results: In vivo binding of [11C]-raclopride compared to [3H]-raclopride was virtually the same. Using [3H]-raclopride, cold raclopride (0.01–0.2 mg/kg) produced 16–77% D2 receptor occupancy and no catalepsy. Raclopride (0.5–2 mg/kg) produced 83–95% D2 occupancy and significant catalepsy. Raclopride (2 mg/kg) produced on average 95% and 87% D2 receptor occupancy 1 and 2 h after administration, respectively, and maximum catalepsy. D2 occupancy at 4, 8 and 24 h was on average 58%, 46%, and 4%, respectively. No catalepsy was observed. Raclopride (0.2 mg/kg), estimated at 70–75% D2 occupancy, produced suppression of CAR. Conclusions: In vivo D2 occupancy measurements in rats using [3H]-raclopride is analogous to using [11C]-raclopride in human PET scanning. Suppression of CAR occurred at a D2 occupancy of around 70–75%, and catalepsy at D2 occupancy >80%. Results closely resembled human studies where 65–70% D2 occupancy was required for antipsychotic response, while ≥80% D2 occupancy led to EPS. Brain mechanisms involved in mediation of catalepsy in rats and EPS in humans might indeed be similar. Both suppression of CAR in rats and antipsychotic response in humans might share an underlying construct, i.e. the need for around 70% D2 receptor blockade.

[1]  M L Wadenberg,et al.  A novel computer-controlled conditioned avoidance apparatus for rats. , 1997, Journal of pharmacological and toxicological methods.

[2]  A. C. V. van Grootheest,et al.  [Atypical antipsychotics]. , 2000, Nederlandsch tijdschrift voor geneeskunde.

[3]  G. Uppfeldt,et al.  Efficacy, safety and tolerability of raclopride, a specific D2 receptor blocker, in acute schizophrenia: an open trial. , 1989, International clinical psychopharmacology.

[4]  S. Ahlénius,et al.  Suppression of conditioned avoidance behavior by the local application of (−)sulpiride into the ventral, but not the dorsal, striatum of the rat , 1990, Biological Psychiatry.

[5]  P. Seeman,et al.  Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. , 1999, The American journal of psychiatry.

[6]  V. Hillegaart,et al.  Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: A comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission , 1986, Pharmacology Biochemistry and Behavior.

[7]  G Blomqvist,et al.  Comparison of the Transient Equilibrium and Continuous Infusion Method for Quantitative PET Analysis of [11C]Raclopride Binding , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  Douglas L. Jones,et al.  From motivation to action: Functional interface between the limbic system and the motor system , 1980, Progress in Neurobiology.

[9]  Christer Halldin,et al.  Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients , 1993, Biological Psychiatry.

[10]  S. Kapur,et al.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.

[11]  M. Wadenberg Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat , 1996, Neuroscience & Biobehavioral Reviews.

[12]  S O Ogren,et al.  Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. , 1985, Biochemical pharmacology.

[13]  P. Seeman,et al.  Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors , 1998, Molecular Psychiatry.

[14]  P. Voorn,et al.  Effects of risperidone and haloperidol on tachykinin and opioid precursor peptide mRNA levels in the caudate‐putamen and nucleus accumbens of the rat , 1998, Synapse.

[15]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[16]  P. Elliott,et al.  Neuroleptic-induced catalepsy as a model of Parkinson's disease I. Effect of dopaminergic agents , 1990, Journal of neural transmission. Parkinson's disease and dementia section.

[17]  G. Sedvall,et al.  Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. , 1988, Archives of general psychiatry.

[18]  Alan A. Wilson,et al.  The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. , 1995, Life sciences.

[19]  A Carlsson,et al.  The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[20]  O. Hornykiewicz,et al.  Morphine catalepsy in the rat: relation to striatal dopamine metabolism. , 1972, European journal of pharmacology.

[21]  M A Geyer,et al.  Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. , 1998, Schizophrenia bulletin.

[22]  R. Baldessarini Drugs and the treatment of psychiatric disorders , 1996 .

[23]  G. Sedvall,et al.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.

[24]  Ching Chun Li,et al.  Introduction to Experimental Statistics , 1965 .

[25]  P. Sanberg Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors , 1980, Nature.

[26]  S. Kapur,et al.  Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. , 1999, The American journal of psychiatry.

[27]  S. Kapur,et al.  High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. , 1996, The American journal of psychiatry.

[28]  P. Seeman,et al.  Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selective for D4 Receptors , 1997, Neuropsychopharmacology.

[29]  P. Hicks,et al.  The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? , 1999, Neuroscience & Biobehavioral Reviews.

[30]  S. Siegel,et al.  Nonparametric Statistics for the Behavioral Sciences , 2022, The SAGE Encyclopedia of Research Design.

[31]  R. Myers,et al.  Quantitation of Carbon‐11‐labeled raclopride in rat striatum using positron emission tomography , 1992, Synapse.

[32]  P. Seeman Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.